Pharmaceuticals

Painreform

PainReform Announces DeepSolar's AI Report Engine, Rated Poorly by TipRanks

Painreform released FY2025 Semi-Annual earnings on October 1, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.0906

Painreform released FY2025 Q2 earnings on October 1, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.5453

Painreform released FY2025 Q1 earnings on October 1, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.5453

PainReform Ltd. Collaborates with LayerBio for Ophthalmic Pain Treatment Clinical Trial

Blade Ranger Holds a Large Number of PainReform Warrants

PainReform and Econergy Launch Solar Plant Pilot Project in Romania

Painreform released FY2024 Q3 earnings on April 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6014 (forecast USD -18.96)

Painreform released FY2024 annual earnings on April 7, 2025 (EST), with actual revenue of USD 0 and actual EPS of USD -32.1644 (forecast EPS USD -78.9599)

Painreform released FY2024 Q4 earnings on April 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6014 (forecast USD -7.68)

Painreform released FY2024 9 Months Earnings on April 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -116.4161

PainReform's Acquisition Boosts Its Competitiveness in AI Solar Management

PainReform Receives Notification from Nasdaq Regarding Minimum Shareholder Equity Requirements

PainReform Ltd Applies for Mixed Listing

Painreform released FY2024 Semi-Annual earnings on August 15 (EST), actual revenue USD 0, actual EPS USD -63.1456

Painreform released FY2024 Q2 earnings on August 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -22.7395 (forecast USD -24.96)

Painreform released FY2024 Q1 earnings on May 15 (EST), actual revenue 0 USD, actual EPS -65.2161 (forecast EPS -14.40)

Painreform released FY2023 annual earnings on February 29, 2024 (EST), with actual revenue of USD 0 and EPS of USD -63.1295 (forecast EPS USD -118.7999)

Painreform released FY2023 Cumulative Q3 Earnings on November 15, 2023 (EST), with Revenue at 0 and EPS at -98.2978

Painreform released FY2023 H1 earnings on August 10 (EST) with revenue of 0 and EPS of -98.88

Aimei Health Tech

Oriental Culture

Netcapital

Lion

JX Luxventure

ALPHAVEST ACQUISITION CORP ORD USD0.0001(S/R 22/01/26)

Designer Brands

Horizon Space Acquisition I

Cypherpunk Tech

Alexander & Baldwin

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap